C4 therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

Watertown, mass., july 17, 2023 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the independent directors serving on the organization, leadership and compensation committee of the company's board of directors approved the grant of non-qualified stock options to purchase an aggregate of 351,000 shares of the company's common stock to two new employees (the “inducement grants”), with grants made on july 10 and july 17, 2023 (the “grant dates”). the inducement grants were granted as inducements material to these individuals entering into employment with c4t in accordance with nasdaq listing rule 5635(c)(4).
CCCC Ratings Summary
CCCC Quant Ranking